B+
Bull case
20%
Probability
Target price
$2.25
Analysis reference price unavailable
Analysis 2026-08-11 · RankAlpha Sentiment Codex
TENX
Tenax TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-08-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-08-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-11
Recent news sentiment (30D)
-0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+10.6
Score
AI commentary
Sentiment is sharply negative after the August 10 LEVEL readout; trusted-news coverage described the shares as sinking after the trial result. The packet does not establish an exact pre-event comparison or provide analyst revisions, so the immediate market reaction is clear but forward valuation remains uncertain. The setup is a low-coverage, high-volatility monitoring situation rather than a high-conviction recovery thesis.
RankAlpha Sentiment Codex - 2026-08-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-11catalystLEVEL Phase 3 topline failure resets the thesisHigh impact
The August 10 filing reported that LEVEL missed its primary 6-minute walk-distance endpoint and key secondary KCCQ endpoint. Exploratory subgroup and biomarker signals were positive but nominal, leaving the readout predominantly negative [#8-K-2026-08-10].
2026-11-09eventFDA Type C meeting and revised development pathHigh impact
Tenax intends to request an FDA Type C meeting to discuss revisions to the ongoing registrational development of TNX-103. Regulatory feedback is the key near-term determinant of whether the subgroup findings support a viable path forward [#8-K-2026-08-10].
2027-12-31catalystLEVEL-2 enrollment and follow-up executionHigh impact
The company previously expected LEVEL-2 enrollment completion by the end of 2027, while the LEVEL open-label extension remains ongoing. Execution, durability, and any protocol changes will determine residual pipeline value after the LEVEL miss [#SEC-8K-2026-07-31].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-11 • Updated nightlySource: Internal modelMethodology